Candesartan and cognitive decline in older patients with hypertension
Candesartan and cognitive decline in older patients with hypertension
复制标题
坎地沙坦与老年高血压患者认知能力下降
作者:
B. Saxby;F. Harrington;K. Wesnes;I. McKeith;Gary A. Ford
Background: Hypertension is associated with impaired cognitive function but the effect of antihypertensive treatment on cognitive function is unclear. Methods: We investigated the effect of treatment of hypertension on cognition with the angiotensin-receptor-blocker, candesartan, in a placebo-controlled, double-blind, randomized controlled trial at one center participating in the Study on Cognition and Prognosis in the Elderly. A total of 257 older adults with hypertension (mean age 76 years, blood pressure 165 ± 8/88 ± 7 mm Hg) were recruited from general practice and treated with 8–16 mg candesartan or placebo once daily, for a mean follow-up period of 44 months. Additional antihypertensive therapy was permitted in both groups to achieve treatment targets. Cognitive function was measured using the Cognitive Drug Research computerized assessment battery, trail-making tests, and verbal fluency. Data from annual assessments were used to calculate individual coefficients of decline by regressing composite test scores over time for five cognitive domains. Results: The blood pressure difference between groups at study close was 8/3 mm Hg. The candesartan group showed less decline in attention (0.004 vs −0.036, p = 0.04) and episodic memory (0.14 vs −0.22, p = 0.04) compared to placebo, a similar trend for speed of cognition (−2.3 vs −17.4, p = 0.15), but no differences in working memory (0.0014 vs 0.0010, p = 0.90) or executive function (−0.0031 vs −0.0023, p = 0.95). Effect sizes were in the small-to-moderate range. Conclusions: The potential for blood pressure–lowering with angiotensin-receptor-blockers to reduce the rate of decline of specific areas of cognitive function in older patients with hypertension warrants further investigation to determine clinical efficacy.
登录
查看更多内容
DOI:
10.1001/jama.1995.03530230032026
发表时间:
1995-12
期刊:
JAMA
影响因子:
--
作者:
L. Launer;K. Masaki;H. Petrovitch;D. Foley;R. Havlik
通讯作者:
L. Launer;K. Masaki;H. Petrovitch;D. Foley;R. Havlik
影响因子:
22.4
作者:
Waldstein,SR;Manuck,SB;Ryan,CM;Muldoon,MF
通讯作者:
Muldoon,MF
影响因子:
5
作者:
ELIAS, MF;WOLF, PA;WHITE, LR
通讯作者:
WHITE, LR
影响因子:
8.3
作者:
Jennings, JR;Muldoon, MF;Manuck, SB
通讯作者:
Manuck, SB